SCHEDULE 13G/A: Wellington Management Group Discloses 7.89% Stake in MBX Biosciences

Wellington Management Group LLP and its affiliated entities have filed an amended Schedule 13G, reporting a beneficial ownership of 7.89% of MBX Biosciences, Inc.'s common stock as of March 31, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 2,638,521 shares of common stock in MBX Biosciences, Inc.
• This aggregate amount represents 7.89% of the issuer's common stock.
• The beneficial ownership is held by clients of Wellington's investment advisers, with Wellington Biomedical Innovation Master Investors (Cayman) II L.P. specifically noted as having rights or power over more than 5% of the class.
• The reporting persons have shared voting power over 2,525,931 shares and shared dispositive power over 2,638,521 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of MBX Biosciences, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in MBX Biosciences, Inc. by a major global asset manager, Wellington Management Group. Such disclosures are common for large investment firms that cross beneficial ownership thresholds, indicating their passive investment positions within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Wellington Management Group may be perceived positively by other shareholders, potentially signaling confidence in the company.

Key Dates

Keywords

MBX Biosciences, Wellington Management Group, Schedule 13G, beneficial ownership, common stock, investment management, institutional investor